USFDA Guidance: Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA & Statistical Approaches to Establishing Bioequivalence

Bioequivalence (BE) plays a critical role in generic drug development by demonstrating that a generic product performs similarly to its reference listed drug (RLD). To support approval of an Abbreviated New Drug Application (ANDA), manufacturers must establish that the proposed generic product delivers a comparable rate and extent of drug absorption under similar conditions of use.

The FDA’s updated guidances, Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA and Statistical Approaches to Establishing Bioequivalence, provide a comprehensive framework covering study design, pharmacokinetic evaluation, statistical analysis, and regulatory expectations for demonstrating bioequivalence.

Together, these guidances help manufacturers develop scientifically robust BE programs while supporting consistent regulatory decision-making for generic drug approvals.

Role of Bioequivalence Studies

Bioequivalence studies are intended to demonstrate that there is no significant difference in drug exposure between a generic product and the reference drug. In most cases, this is achieved through pharmacokinetic studies that compare systemic drug concentrations after administration of the test and reference products.

The primary pharmacokinetic parameters evaluated include:

• Maximum plasma concentration (Cmax)

• Area under the concentration-time curve (AUC)

• Total systemic exposure measurements

These endpoints help regulators determine whether the generic product can be expected to provide the same therapeutic performance as the reference product.

Pharmacokinetic Study Design Considerations

The FDA continues to recommend single-dose crossover studies as the preferred design for most bioequivalence assessments because they are sensitive in detecting formulation differences.

However, alternative approaches may be appropriate depending on the product characteristics.

Replicate Designs

Replicate crossover studies are particularly useful for highly variable drugs and narrow therapeutic index (NTI) products. These designs allow better estimation of within-subject variability and support specialized statistical approaches when necessary.

Parallel Designs

Parallel studies may be considered when crossover studies are impractical, such as for drugs with very long half-lives.

Adaptive Designs

The updated guidance also recognizes adaptive study designs, which allow certain predefined study modifications based on accumulating data while maintaining statistical validity.

Study Population and Conduct

Healthy adult volunteers are generally recommended for bioequivalence studies unless safety concerns require patient participation.

The guidance recommends careful consideration of:

• Subject selection criteria

• Safety monitoring

• Sample size determination

• Study conditions

• Data quality and bioanalytical accuracy

Manufacturers are also expected to submit information from pilot studies and failed studies conducted using the same formulation.

Fasting and Fed Bioequivalence Studies

Food can significantly affect drug absorption and may influence different formulations differently.

For many immediate-release products, fasting studies may be sufficient. However, products with a greater risk of food-related variability may require both fasting and fed studies.

Modified-release products generally require evaluation under both conditions to ensure consistent performance across real-world use scenarios.

These recommendations help ensure that formulation-dependent food effects are adequately assessed before approval.

Statistical Assessment of Bioequivalence

While pharmacokinetic studies generate the necessary exposure data, statistical analysis ultimately determines whether bioequivalence has been established.

The FDA continues to support a science-based statistical framework focused on demonstrating that differences between the test and reference products remain within acceptable regulatory limits.

Average Bioequivalence

Average Bioequivalence (ABE) remains the primary regulatory approach for most generic products.

Under this method, pharmacokinetic parameters are statistically compared using confidence interval analysis. Bioequivalence is generally established when the 90% confidence interval for the ratio of test to reference product falls within the acceptance range of:

80.00% to 125.00%

This standard continues to serve as the foundation of most generic drug approvals.

Logarithmic Transformation

The FDA recommends logarithmic transformation of pharmacokinetic data before analysis because it improves statistical reliability and supports more accurate estimation of confidence intervals.

Parameters such as Cmax and AUC are therefore typically analyzed on the log scale before interpretation.

Highly Variable Drugs and NTI Products

Certain products require additional statistical considerations.

Highly variable drugs often demonstrate substantial within-subject variability, making conventional approaches less efficient. For these products, replicate study designs and reference-scaled bioequivalence methods may be used.

Narrow therapeutic index drugs require greater precision because small differences in exposure may lead to clinically significant changes in safety or effectiveness. As a result, more rigorous study designs and statistical evaluations are often recommended.

Missing Data and Outlier Management

The updated statistical guidance places greater emphasis on prospectively defining approaches for handling missing data, protocol deviations, and intercurrent events.

The FDA advises against removing data solely because observations appear unusual. Exclusion should only occur when supported by documented protocol violations or confirmed analytical issues.

This approach helps maintain study integrity and minimizes the risk of biased conclusions.

References

1. FDA Guidance for Industry: Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA (May 2026)

2. FDA Guidance for Industry: Statistical Approaches to Establishing Bioequivalence (May 2026)